Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Neogen's enterprise value was $3.91B on Nov 11, 2026, against $2.75B a year earlier. Over the last 5 years it ranged from $1.08B to $6.55B, with a median of $3.57B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.91B | +31.7% |
| 2025 | Dec 31, 2025 | $2.97B | -12.6% |
| 2024 | Dec 31, 2024 | $3.40B | -32.0% |
| 2023 | Dec 29, 2023 | $5.00B | +286.2% |
| 2022 | Dec 30, 2022 | $1.29B | -71.1% |
| 2021 | Dec 31, 2021 | $4.48B | +16.7% |
| 2020 | Dec 31, 2020 | $3.84B | +22.6% |
| 2019 | Dec 31, 2019 | $3.13B | +14.3% |
| 2018 | Dec 31, 2018 | $2.74B | -8.2% |
| 2017 | Dec 29, 2017 | $2.98B | -6.5% |
| 2016 | Dec 30, 2016 | $3.19B | +17.9% |
| 2015 | Dec 31, 2015 | $2.71B | +15.0% |
| 2014 | Dec 31, 2014 | $2.35B | +10.4% |
| 2013 | Dec 31, 2013 | $2.13B | +56.3% |
| 2012 | Dec 31, 2012 | $1.36B | +50.9% |
| 2011 | Dec 30, 2011 | $903.89M | -27.1% |
| 2010 | Dec 31, 2010 | $1.24B | – |
See a number that looks wrong?